Over $27M Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at RumbleON, Zymeworks, and Kura Oncology have made notable stock purchases, signaling confidence in their respective companies. RumbleON appointed Mark Tkach as Interim CEO, Zymeworks announced the departure of President and COO Neil Klompas, and Kura Oncology reported pricing of a $100 million public offering.
June 22, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Director Thomas Malley bought 50,000 shares of Kura Oncology at an average price of $11.50, totaling $575,000, after the company reported pricing of a $100 million public offering.
The insider purchase of 50,000 shares by Director Thomas Malley signals confidence in Kura Oncology's prospects following the announcement of a $100 million public offering. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Stone House Capital Management acquired 250,000 shares of RumbleON at an average price of $10.45, totaling $2.61 million, following the appointment of Mark Tkach as Interim CEO.
The insider purchase of 250,000 shares by Stone House Capital Management signals confidence in RumbleON's prospects following the appointment of Mark Tkach as Interim CEO. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Ecor Capital LLC acquired 3,350,000 shares of Zymeworks at an average price of $8.12, totaling $27.2 million, after the announcement of President and COO Neil Klompas' departure.
The insider purchase of 3,350,000 shares by Ecor Capital LLC signals confidence in Zymeworks' prospects despite the departure of President and COO Neil Klompas. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100